Singapore, January 23, 2026 — Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), announced today that it has received a notification from Nasdaq indicating that, based on the closing bid price of the Company’s shares over the past 30 consecutive business days, the Company no longer meets the requirements under Nasdaq’s Listing Rules (the “Rules”) for listed securities to maintain a minimum bid price of $1 per share.
The Rules grant the Company a 180-calendar-day compliance period to regain compliance. If, at any point during this 180-day period, the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide written confirmation of compliance. Should the Company choose to implement a reverse stock split, it must complete the split no later than ten business days prior to the expiration date of July 21, 2026, to regain compliance. If the Company fails to regain compliance, it may be eligible for additional time. To qualify, the Company must meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards of The Nasdaq Capital Market (excluding the bid price requirement) and must submit written notice of its intent to resolve the deficiency during the second compliance period, which may involve a reverse stock split if necessary. If the Company fulfills these requirements, Nasdaq will inform it that an additional 180 calendar days have been granted. However, if Nasdaq Staff determines that the Company is unlikely to resolve the deficiency or if the Company is otherwise ineligible, Nasdaq will notify that its securities may be subject to delisting.
The Company is currently working with its professional advisors to develop a corrective plan to address the aforementioned non-compliance. Trading of the Company’s shares on Nasdaq is not currently impacted by this non-compliance.
About Basel Medical Group Ltd
Basel Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine, orthopedic procedures and surgeries, along with neurosurgical treatments, executive health screening services, occupational medicine, rehabilitation, mental and women’s health, and general practices. Our operations are centered in Singapore, with our clinics located at Suntec City Mall, Macpherson Road, Toa Payoh, Margaret Drive, Tampines, Gateway East, and Gleneagles Medical Centre. Over the past 20 years, our group has established strong and enduring relationships with a large corporate client base, particularly those in the construction, marine, and oil & gas industries, which support our robust business model. As a medical service provider in Singapore with over 20 years of experience, we are well-positioned to capitalize on growth opportunities in the private healthcare industry in Singapore and across Southeast Asia, driven by aging populations, rising income levels, increasing private insurance coverage, government efforts and spending on healthcare, a growing rate of sports participation, and Singapore’s status as a top destination for healthcare services in Asia. Our management and medical practitioner team includes a roster of orthopedic and neurosurgery specialists, general practitioners, corporate finance experts, and healthcare partnership specialists. Basel Medical Group Ltd acts as the holding company for our group, and we conduct our operations through our operating subsidiaries based in Singapore. For more information, please visit the Company’s website: .
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, which involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections regarding future events that could impact its financial condition, operating results, business strategy, and financial requirements. Investors can identify many (though not all) of these statements through the use of terms such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would”, or other similar expressions in this press release. The Company has no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as required by law. While the Company believes the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee they will be accurate, and the Company warns investors that actual results may differ significantly from the expected results, encouraging them to review other factors that could affect future results in the Company’s filings with the SEC.
Media Contact:
Basel Medical Group Ltd
+65 6291 9188
